Every Form 4 that Lantern Pharma Inc. (LTRN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LTRN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LTRN filings page.
Lantern Pharma Inc. director Lee Troy Schalop reported buying company securities. He acquired 48,544 shares of common stock at $2.06 per share in an open-market purchase, resulting in direct ownership of 48,544 shares after the transaction.
On the same date, he also acquired common stock purchase warrants covering 48,544 underlying shares, with a conversion or exercise price of $2.27 per share and an expiration date of November 13, 2031. According to the disclosure, these warrants were obtained in an offering of securities that closed on May 14, 2026 and will be exercisable starting on November 14, 2026.
Lantern Pharma Inc. director Jeffrey D. Keyser reported buying common stock and warrants. He acquired 48,544 shares of common stock in an open-market purchase at $2.06 per share, bringing his direct holdings to 94,303 shares. He also bought 48,544 common stock purchase warrants with an exercise price of $2.27 per share, each for 48,544 underlying shares of common stock. The securities were acquired in the company’s offering of securities that closed on May 14, 2026, and the warrants are exercisable starting November 14, 2026 and expire on November 13, 2031.
Lantern Pharma Inc. reported that director D. Jeffrey Keyser received two grants of stock options in the company. On January 9, 2026, he was awarded a stock option to buy 25,000 shares of common stock at an exercise price of $3.49 per share and a second stock option to buy 28,844 shares of common stock at the same $3.49 exercise price.
The first option for 25,000 shares will vest in equal monthly installments over 24 months starting February 9, 2026. The second option for 28,844 shares will vest in equal monthly installments over 12 months starting February 9, 2026. Both grants were made under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan, and the filing shows these option holdings as directly owned by the reporting person.
Lantern Pharma Inc. director Maria-Luisa Maccecchini reported receiving two stock option grants. On January 9, 2026, she was awarded a stock option to buy 25,000 shares of common stock at an exercise price of $3.49 per share, with the option priced at $0.00 on the grant date. She also received a second stock option for 21,152 shares at the same $3.49 exercise price.
Both grants were made under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The 25,000-share option vests in equal monthly installments over 24 months starting February 9, 2026, while the 21,152-share option vests in equal monthly installments over 12 months beginning on the same date. Following these grants, she directly beneficially owns 25,000 and 21,152 derivative securities, respectively.
Lantern Pharma Inc. director Chandru Vijay reported receiving two new stock option grants. On January 9, 2026, he was granted stock options to buy 25,000 shares of common stock at an exercise price of $3.49 per share under the company’s Amended and Restated 2018 Stock Incentive Plan. These options vest in equal monthly installments over 24 months starting February 9, 2026.
On the same date, he also received stock options to buy an additional 17,307 shares of common stock at an exercise price of $3.49 per share under the same plan. This second grant vests in equal monthly installments over 12 months beginning February 9, 2026. Both grants are reported as directly owned derivative securities.
Lantern Pharma director Lee Troy Schalop reported new equity awards on a Form 4. On January 9, 2026, he received two grants of stock options (rights to buy common stock) with an exercise price of $3.49 per share. One grant covers 25,000 options that vest in equal monthly installments over 24 months starting February 9, 2026. The second grant covers 18,460 options that vest in equal monthly installments over 12 months starting the same date. Both awards were reported at a transaction price of $0.00 per option, reflecting that these are option grants rather than open-market purchases or sales.
Lantern Pharma Inc. director David S. Silberstein reported receiving two grants of stock options to buy the company’s common stock. On January 9, 2026, he was awarded 25,000 stock options with an exercise price of $3.49 per share under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. These options vest in equal monthly installments over 24 months starting February 9, 2026.
On the same date, he also received an additional 17,307 stock options with the same $3.49 exercise price under the same plan. This second grant vests in equal monthly installments over 12 months beginning on February 9, 2026. Both grants are held directly by Silberstein and represent compensation in the form of equity incentives rather than an open‑market purchase.